Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22
- 8 November 2010
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 30 (11) , 1290-1301
Abstract
Metastasis in breast cancer carries a disproportionately worse prognosis than localized primary disease. To identify microRNAs (miRNA) involved in metastasis, the expression of 254 miRNAs was measured across the following cell lines using microarray analysis: MDA-MB-231 breast cancer cells, cells that grew as a tumor in the mammary fat pad of nude mice (TMD-231), metastatic disease to the lungs (LMD-231), bone (BMD-231) and adrenal gland (ADMD-231). A brain-seeking variant of this cell line (231-BR) was used additionally in validation studies. Twenty miRNAs were upregulated and seven were downregulated in metastatic cancer cells compared with TMD-231 cells. The expression of the tumor suppressor miRNAs let-7 and miR-22 was consistently downregulated in metastatic cancer cells. These metastatic cells expressed higher levels of putative/proven miR-22 target oncogenes ERBB3, CDC25C and EVI-1. Introduction of miR-22 into cancer cells reduced the levels of ERBB3 and EVI-1 as well as phospho-AKT, an EVI-1 downstream target. The miR-22 primary transcript is located in the 5′-untranslated region of an open reading frame C17orf91, and the promoter/enhancer of C17orf91 drives miR-22 expression. We observed elevated C17orf91 expression in non-basal subtype compared with basal subtype breast cancers. In contrast, elevated expression of EVI-1 was observed in basal subtype and was associated with poor outcome in estrogen receptor-negative breast cancer patients. These results suggest that metastatic cancer cells increase specific oncogenic signaling proteins through downregulation of miRNAs. Identifying such metastasis-specific oncogenic pathways may help to manipulate tumor behavior and aid in the design of more effective targeted therapies.Keywords
This publication has 49 references indexed in Scilit:
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapyClinical Cancer Research, 2010
- miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant MetastasesPLOS ONE, 2009
- The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional responseProceedings of the National Academy of Sciences, 2009
- Estradiol-regulated microRNAs control estradiol response in breast cancer cellsNucleic Acids Research, 2009
- Widespread microRNA repression by Myc contributes to tumorigenesisNature Genetics, 2007
- MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtypeGenome Biology, 2007
- Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation SeriesClinical Cancer Research, 2007
- NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2Oncogene, 2006
- Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase InhibitionJournal of Biological Chemistry, 2006
- Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression functionBritish Journal of Cancer, 2004